StockNews.AI
TLPH
StockNews.AI
12 days

Talphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025

1. Talphera will release Q2 2025 financial results on August 14, 2025. 2. A conference call will follow the earnings release for investor updates. 3. Talphera's lead product, Niyad™, is under FDA's Breakthrough Device Designation. 4. Focus on innovative therapies for medically supervised settings is emphasized.

Earnings
+4.6%Current Return
VS
+0.78%S&P 500
$0.391508/07 04:40 PM EDTEvent Start
$0.409508/08 10:58 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

The upcoming earnings report could stabilize or slightly alter stock price sentiment.

How important is it?

The planned release of earnings could influence market perception and investor behavior around TLPH.

Why Short Term?

Investor sentiment may shift due to immediate financial results; long-term impacts depend on product reception.

Related Companies

N/A
, /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2025 financial results after market close on Thursday, August 14, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link posted within Investors/News & Events/Upcoming Events section. The webcast will include a slide presentation and a replay will be available on the Talphera website for 90 days following the event. Conference Call Information Investors who wish to participate in the conference call may do so by dialing 1-800-836-8184 for North American callers, or 1-646-357-8785 (toll applies) for international callers outside of Canada. The conference ID is 32530. About Talphera, Inc. Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA). This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com. SOURCE Talphera, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News